Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

11-03-2018 | Premixed insulins | Review | Article

Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care

Journal: Diabetes Therapy

Authors: Sanjay Kalra, Leszek Czupryniak, Gary Kilov, Roberta Lamptey, Ajay Kumar, A. G. Unnikrishnan, Aissa Boudiba, Mohamed Abid, Zhanay A. Akanov, Ali Latheef, Mustafa Araz, Ralph Audehm, Silver Bahendeka, Naby Balde, Sandeep Chaudhary, Chaicharn Deerochanawong, Olufemi Fasanmade, Hinde Iraqi, Tint Swe Latt, Jean Claude Mbanya, Joel Rodriguez-Saldana, Ko Seung Hyun, Zafar A. Latif, Maxim Lushchyk, Magdy Megallaa, Mohammed Wali Naseri, Nguyen Quang Bay, Kaushik Ramaiya, Hoosen Randeree, Syed Abbas Raza, Khalid Shaikh, Dina Shrestha, Eugene Sobngwi, Noel Somasundaram, Norlela Sukor, Rima Tan

Publisher: Springer Healthcare

Login to get access

Abstract

Premixed insulins are an important tool for glycemic control in persons with diabetes. Equally important in diabetes care is the selection of the most appropriate insulin regimen for a particular individual at a specific time. Currently, the choice of insulin regimens for initiation or intensification of therapy is a subjective decision. In this article, we share insights, which will help in rational and objective selection of premixed formulations for initiation and intensification of insulin therapy. The glycemic status and its variations in a person help to identify the most appropriate insulin regimen and formulation for him or her. The evolution of objective glucometric indices has enabled better glycemic monitoring of individuals with diabetes. Management of diabetes has evolved from a ‘glucocentric’ approach to a ‘patient-centered’ approach; patient characteristics, needs, and preferences should be evaluated when considering premixed insulin for treatment of diabetes.
Funding: Novo Nordisk, India.
Literature
1.
2.
International Diabetes Federation. IDF diabetes atlas. 8th ed. 2017. http://​www.​diabetesatlas.​org/​across-the-globe.​html. Accessed 21 June 2018.
3.
Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Xenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991–7.CrossRef
4.
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753–60.CrossRef
5.
Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of b-cell function. Diabetes Care. 2004;27(11):2597–602.CrossRef
6.
Hu Y, Li L, Xu Y, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and b-cell function in subjects with long-term remission. Diabetes Care. 2011;34(8):1848–53.CrossRef
7.
Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(8):638–52.CrossRef
8.
Meneghini L. New insulin preparations: a primer for the clinician. Cleve Clin J Med. 2016;83(5 Suppl 1):S27–33.CrossRef
9.
Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–9.CrossRef
10.
American Diabetes Association. Standards of medical care in diabetes—2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–5.
11.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24(1):91–120.CrossRef
12.
Silver B, Ramaiya K, Andrew SB, et al. EADSG guidelines: insulin therapy in diabetes. Diabetes Ther. 2018;9(2):449–92.PubMedPubMedCentral
13.
Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries. 2018;38(1):1–15.CrossRef
14.
The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee. The 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. JEMDSA 2017;21 Suppl 1: S1–S196.
15.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64–74.CrossRef
16.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.CrossRef
17.
The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–2018. East Melbourne: RACGP; 2016.
18.
Gunton JE, Cheung NW, Davis TME, et al. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Med J Aust. 2014;201(11):650–3.CrossRef
19.
Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract. 2009;63:1571–7.CrossRef
20.
Wu T, Betty B, Downie M, et al. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. Diabetes Ther. 2015;6:273–87.CrossRef
21.
Mohan V, Kalra S, Kesavadev J, Singh K, Kumar A, Unnikrishnan UG, et al. Consensus on initiation and intensification of premix insulin in type 2 diabetes management. J Assoc Physicians India. 2017;65:59–73.PubMed
22.
Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167:287–94.CrossRef
23.
Kalra S, Latif ZA, Comlekci A, et al. Pragmatic use of insulin degludec/insulin aspart co-formulation: a multinational consensus statement. Indian J Endocrinol Metab. 2016;20(4):542–5.CrossRef
24.
Sheu WH, Ji L, Lee WJ, Jabbar A, Han JH, Lew T. Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: a systematic review. J Diabetes Investig. 2017;8(4):518–34.CrossRef
25.
Rodbard HW. Therapy progression after basal insulin: GLP-1 agonists vs. prandial insulin vs. pre-mixed insulin. 78th Scientific Sessions. American Diabetes Association. 22–26 June, 2018. Orlando, FL, USA.
26.
Downie M, Kilov G, Wong J. Initiation and intensification strategies in type 2 diabetes management: a comparison of basal plus and premix regimens. Diabetes Ther. 2016;7(4):641–57.CrossRef
27.
Giugliano D, Chiodini P, Maiorino MI, Bellastella G, et al. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016;51:417–28.CrossRef
28.
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–5.CrossRef
29.
Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med. 2005;22(4):374–81.CrossRef
30.
Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S. Curr Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Med Res Opin. 2009;25(12):2887–94.CrossRef
31.
Das AK, Sahay BK, Seshiah V, et al. Indian National Consensus Group: national guidelines on initiation and intensification of insulin therapy with premixed insulin analogs. API India, Medicine Update 2013; Chapter 51:227–236.
32.
Kalra S, Gupta Y. Insulin initiation: bringing objectivity to choice. J Diabetes Metab Disord. 2015;14(1):17.CrossRef
33.
Deed G, Kilov G, Dunning T, Cutfield R, Overland J, Wu T. Use of 50/50 premixed insulin analogs in type 2 diabetes: systematic review and clinical recommendations. Diabetes Ther. 2017;8(6):1265–96.CrossRef
34.
Brod M, Kongsø JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18(1):23–32.CrossRef
35.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7.CrossRef
36.
Indian National Consensus Group. Premix insulin: initiation and continuation guidelines for management of diabetes in primary care. J Assoc Physicians India. 2009;57(Suppl):42–6.
37.
Kataoka M, Venn BJ, Williams SM, Te Morenga LA, Heemels IM, Mann JI. Glycaemic responses to glucose and rice in people of Chinese and European ethnicity. Diabet Med. 2013;30(3):e101–7.CrossRef
38.
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, et al. Multinational consensus: insulin initiation with insulin degludec/aspart (IDegAsp). Adv Ther. 2018;23:1–9.
39.
Kalra S, Baruah MP, Sahay R, Kishor K. Pentads and hexads in diabetes care: numbers as targets; numbers as tools. Indian J Endocrinol Metab. 2017;21(6):794–6.CrossRef
40.
Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990;39:1381–90.CrossRef
41.
Kalra S, Gupta Y. Number-based approach to insulin taxonomy. Diabetes Ther. 2015;6(4):469–79.CrossRef
42.
Wu T. Premixed insulin analogues: a new look at an established option. Diabetes Prim Care Aust. 2016;1:129–33.
43.
Kalra S, Plata-Que T, Kumar D, Mumtaz M, Søndergaard F, Kozlovski P, Bebakar WM. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract. 2010;88(3):282–8.CrossRef
44.
Kalra S, Balhara YBS. Insulin distress. US Endocrinol. 2018;14(1):27–9.CrossRef
45.
Kalra S, Gupta Y, Sahay R. The law of therapeutic parsimony. Indian J Endocr Metab. 2016;20:283–4.CrossRef
46.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.CrossRef
47.
Wang JS, Tu ST, Lee IT, Lin SD, Lin SY, Su SL, Lee WJ, Sheu WH. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27(1):79–84.CrossRef
48.
Woerle H, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Göke B. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–5.CrossRef
49.
Beisswenger P, Heine RJ, Leiter LA, Moses A, Tuomilehto J. Prandial glucose regulation in the glucose triad: emerging evidence and insights. Endocrine. 2004;25(3):195–202.CrossRef
50.
Brito M, Ligthelm RJ, Boemi M, Kumar A, Raz I, Koblik T, Gao Y, Christiansen JS. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: a consensus statement. Indian J Endocrinol Metab. 2011;15(3):152–60.CrossRef
51.
Su Q, Liu C, Zheng H, Zhu J, Li PF, Qian L, Yang WY. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): subgroup analysis of a phase 4 open-label randomized trial. J Diabetes. 2017;9(6):575–85.CrossRef
52.
Zafar MI, Ai X, Shafqat RA, Gao F. Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes. Ther Clin Risk Manag. 2015;11:27–32.PubMed
53.
Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, de la Torre M López, Liebl A. Three different premixed combinations of biphasic insulin aspart—comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab. 2009;11(7):700–8.CrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits